Metastatic Malignant Neoplasm to the Leptomeninges Recruiting Phase 1 / 2 Trials for Pertuzumab (DB06366)

Also known as: Leptomeningeal Metastasis / Neoplastic Meningitis / Leptomeningeal Metastases / Metastatic Malignant Neoplasm in the Leptomeninges / Leptomeningeal Disease (LMD) / Leptomeningeal Disease / Lymphomatous meningitis / Leptomeningeal Carcinomatosis / Metastatic malignant neoplasm to leptomeninges (disorder) / Lymphomatous meningitis (disorder) / Malignant meningitis (disorder) / Leptomeningeal Neoplasms / Meningeal dissemination / Metastases to meninges / Meningeal Carcinomatosis

IndicationStatusPhase
DBCOND0057483 (Metastatic Malignant Neoplasm to the Leptomeninges)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04588545Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal DiseaseTreatment